Prostate cancer, PSA, and questions that can only be answered by clinical trials - The Moul/Banez/Freedland article reviewed

被引：0
|
作者：
Ward, John F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
来源：
ONCOLOGY-NEW YORK | 2007年 / 21卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1452 / +
页数：2
相关论文
共 22 条
  • [21] Single-center, retrospective, evaluator-blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2-miR-H9/hsa-miR-3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone
    Kim, Won Tae
    Kim, Kyeong
    Kang, Ho Won
    Byun, Young Joon
    Piao, Xuan-Mei
    Kim, Yong-June
    Lee, Sang Cheol
    Yun, Seok Joong
    Ha, Yun-Sok
    Kim, Jiyeon
    Kim, Isaac Yi
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [22] The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b
    Porcaro, Antonio Benito
    Panunzio, Andrea
    Orlando, Rossella
    Montanaro, Francesca
    Baielli, Alberto
    Artoni, Francesco
    Gallina, Sebastian
    Bianchi, Alberto
    Mazzucato, Giovanni
    Serafin, Emanuele
    Patuzzo, Giulia Marafioti
    Veccia, Alessandro
    Rizzetto, Riccardo
    Brunelli, Matteo
    Migliorini, Filippo
    Bertolo, Riccardo
    Tafuri, Alessandro
    Cerruto, Maria Angela
    Antonelli, Alessandro
    INTERNATIONAL BRAZ J UROL, 2024, 50 (04): : 450 - 458
123